Cantor Fitzgerald Initiates Coverage On Atrium Therapeutics with Overweight Rating, Announces Price Target of $25

Benzinga Newsdesk www.benzinga.com Neutral 64.1%

Neg 0% Neu 64.1% Pos 0%

Cantor Fitzgerald analyst Kristen Kluska initiates coverage on Atrium Therapeutics (NASDAQ:RNA) with a Overweight rating and announces Price Target of $25.